Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis

dc.contributor.authorHeilberg, I. P.
dc.contributor.authorHernandez, E.
dc.contributor.authorAlonzo, E.
dc.contributor.authorValera, R.
dc.contributor.authorFerreira, L. G.
dc.contributor.authorGomes, S. A.
dc.contributor.authorBellorin-Font, E.
dc.contributor.authorWeisinger, JR
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionCent Univ Venezuela
dc.date.accessioned2016-01-24T12:37:35Z
dc.date.available2016-01-24T12:37:35Z
dc.date.issued2005-01-01
dc.description.abstractThe estrogen receptor (ER) gene has been considered as a candidate genetic marker for osteoporosis, and PvuII and XbaI polymorphisms of the ER alpha gene have been associated with low bone mineral density (BMD). We investigated whether ER polymorphism could predict the response of BMD in 28 postmenopausal women on hemodialysis with marked osteopenia or osteoporosis, randomized to receive raloxifene, a selective estrogen receptor modulator (SERM), or placebo for I year. BMD was assessed by dual X-ray absorptiometry and PvuII and XbaI restriction fragment-length polymorphism of the ER gene was determined using polymerase chain reaction. Baseline lumbar spine or femoral neck BMD parameters were not different between patients presenting either homozygous PP or xx when compared with heterozygous Pp or Xx genotypes. After 1 year, patients on raloxifene, presenting with PP or xx genotypes (but not those with Pp or Xx), showed a significantly higher mean lumbar spine BMD (0.942 +/- 0.18 vs. 0.925 +/- 0.17 2 g/cm(2), p <.01) and lower serum pyridinoline (19.7 +/- 9.7 vs. 30.6 +/- 16.5 nmol/L, p <.02) when compared with baseline values. No changes were detected in the placebo-treated patients or in the femur neck sites. in conclusion, after I year on raloxifene, postmenopausal osteoporotic women on chronic hemodialysis, homozygous for the P or x (PP or xx) alleles of the ER, exhibited a better lumbar spine BMD response and decreased serum pyridinoline values when compared with heterozygous women (Pp or Xx), suggesting that ER alpha allelic variants may explain, at least in part, the different outcomes after treatment of osteoporosis with SERM.en
dc.description.affiliationUniversidade Federal de São Paulo, Div Nephrol, BR-04023900 São Paulo, Brazil
dc.description.affiliationCent Univ Venezuela, Div Nephrol, Hosp Univ Caracas, Caracas, Venezuela
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Nephrol, BR-04023900 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent155-161
dc.identifierhttp://dx.doi.org/10.1081/JDI-48241
dc.identifier.citationRenal Failure. Philadelphia: Taylor & Francis Inc, v. 27, n. 2, p. 155-161, 2005.
dc.identifier.doi10.1081/JDI-48241
dc.identifier.issn0886-022X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28098
dc.identifier.wosWOS:000227929600005
dc.language.isoeng
dc.publisherTaylor & Francis Inc
dc.relation.ispartofRenal Failure
dc.rightsAcesso restrito
dc.rights.licensehttp://journalauthors.tandf.co.uk/permissions/reusingOwnWork.asp
dc.subjectestrogen receptor polymorphismen
dc.subjectbone mineral densityen
dc.subjectpostmenopausal osteoporosisen
dc.subjectselective estrogen receptor modulatoren
dc.subjectraloxifeneen
dc.titleEstrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysisen
dc.typeArtigo
Arquivos